99%min Montelukast Sodium For Antiasthma API CAS 151767-02-1 CAS NO.151767-02-1

Min.Order Quantity:: 10 Gram

Purity:: 99%

Port:: Wuhan

Payment Terms:: T/T,MoneyGram

Add to Inquiry Cart

Product Details

Keywords

99% Montelukast Sodium
API Manufacturer
For Treat Asthma

Quick Details

ProName: 99%min Montelukast Sodium For Antiasth...
CasNo: 151767-02-1
Molecular Formula: C35H35ClNNaO3S
Appearance: White Powder
Application: It Can Be Used As Pharmaceutical Inte...
DeliveryTime: 2-4 days after confirming your payment...
PackAge: 100g/ bag, 2 kg/ bag, 25kg/ carton or ...
Port: Wuhan
ProductionCapacity: 10000 Metric Ton/Month
Purity: 99%
Storage: Store in sealed containers at cool & d...
Transportation: By DHL, TNT, FedEx, HKEMS, UPS, Etc
LimitNum: 10 Gram

Superiority

advantages:

hubei xinrunde chemical co., ltd is a renowned pharmaceutical manufacturer. we can offer high quality products at competitive price in quick delivery with 100% custom pass guaranteed. never stop striving to offer our best service is our philosophy. we have flexible and untraceable payment terms. as a leading manufacture, our products have been exported to germany, norway, poland, finland, spain, uk, france, russia, usa, brazil, mexico, australia, japan, korea, thailand, indonesia, uruguay and many other countries.

1. quality.every batch of steroid powders have tobetested by our qc(quality control) before they are allowed to sell.

2. delivery we have stock, so we can delivery quickly at the very day when receive the payment. within 24 hours after receiving the payment lead time 4 or 7 days.

3. discreet package safelyand professionally disguised package guaranteed. for your safety and to insure delivery all products will be packed in a discreet way to prevent any suspicions, no steroids related name will appear on the parcels. high successful delivery rate.

4. warm after-sale service any of your question would be solved for the first as soon as possible.

Details

montelukast sodium basic information

pharmacological effect uses

product name:	montelukast sodium
synonyms:	singulair;montelukast na;montelukast sodium;mk-476;2-[1-[[1-[3-[2-[(7-chloro-2-quinolyl)]vinyl]phenyl]-3-[2-(1-hydroxy-1-methyl-ethyl)phenyl]-propyl]sulfanylmethyl]cyclopropyl]acetic acid sodium salt;1-[1-[[[(1r)-1-[3-[(1e)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic;mk-476, singulair;montelukast, sodium salt
cas:	151767-02-1
mf:	c35h35clnnao3s
mw:	608.17
einecs:
product categories:	active pharmaceutical ingredients;apis;chiral reagents;intermediates & fine chemicals;pharmaceuticals;sulfur & selenium compounds;isotope labeled compounds;pharmaceutical intermediates;dioxyline;other apis;inhibitors
mol file:	151767-02-1.mol

montelukast sodium chemical properties

storage temp.	-20°c freezer, under inert atmosphere
solubility	dmso: ≥8mg/ml at 60°c
color	white to tan
merck	14,6258

safety information

hazard codes	xi
risk statements	63-41-62
safety statements	26
rtecs	gz0698000

msds information

montelukast sodium usage and synthesis

pharmacological effect	cysteinyl leukotrienes (ltc4, ltd4, lte4) is a eicosane-type substance released by various kinds of cells including mast cells and eosinophils with strong inflammatory effect. these important asthma pre-inflammatory mediators can bind to the cysteinyl leukotriene receptors (cyslt) identified in the human airways, resulting in a variety of airway responses including bronchoconstriction, mucus secretion, increased vascular permeability, and eosinophil accumulation. montelukast sodium is an orally active selective leukotriene receptor antagonist that can specifically inhibit the cysteinyl leukotriene receptor. it was successfully developed by the merck company (german) and had entered into market in canada, finland, and mexican in 1997. it is suitable for the prevention and long-term treatment of adults and children asthma, including the prevention of daytime and nighttime asthma symptoms, the treatment of asthma patients who are aspirin-sensitive and prevention of exercise-induced bronchial contraction, it can also be used to relieve the seasonal allergic rhinitis symptoms of 15 year-old or over 15 year-old patients whose symptoms are invalid and intolerant to other treatment. montelukast is a selective leukotriene receptor antagonist and has been approved for the oral administration treatment of asthma and allergic rhinitis. it is also a potent oral preparation that can significantly improve the inflammatory indicators. biological determination of biochemistry and pharmacology has showed that montelukast sodium has a high affinity and selectivity to the cyslt1 receptors (compared with other kinds of pharmacologically important airway receptors such as prostanoid, cholinergic and β-adrenergic receptors). montelukast can effectively suppress the physiological effects caused by the binding between ltc4, ltd4 and lte4 receptor and cyslt1 receptor without any receptor agonistic activity. there is the secondary type of cysteinyl leukotriene receptor (cyslt2) presented in the lungs cysteinyl leukotriene receptor but may be limited to the blood vessels. so far, researchers haven’t cloned two receptors so the situation of cyslt receptor is illustrated through binding assay and pharmacological analysis. it has been now thought that montelukast does not antagonize cyslt2 receptors. the above information is edited by the chemicalbook of dai xiongfeng.
uses	it can be applied to alleviate the symptoms caused by allergic rhinitis.
uses	a selective leukotriene d4-receptor antagonist. used as an antiasthmatic
uses	antiinfective
uses	a potent and highly selective cyslt1 receptor antagonist, without demonstrated cyslt2 activity